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Background: Published studies concerning the impact of specialist care on lung disease in cystic fibrosis remain limited and most are either biased
due to comparison with historical controls and/or underpowered.
Methods: In this retrospective multicentric study, data from all CF children fulfilling the following criteria were collected: 1) Age 6–b18 at the
end of 2003; 2) diagnosis before 8 y; 3) follow-up in an accredited CF Belgian centre; 4) at least 1 spirometry and respiratory culture available for
2003. Group A included children referred ≥2 years after the diagnosis. Patients from Group A were then matched with a single early referred
patient on the basis of 2 criteria: same centre, as closest age as possible (Group B).
Results: Data from 217 children were collected (Group A: 67/217). Late referred patients had a lower FEV1 (77.2%±22.4 vs 86.7% pred.±19.4,
p=0.01) and a higher prevalence of Pseudomonas aeruginosa (38.6 vs 17.5%, pb0.05).
Conclusion: In this population of CF children, a delay of 6.1 y (vs 0.1 y) between diagnosis and referral to a specialist clinic resulted in poorer
respiratory outcome at age 13.
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The prognosis of cystic fibrosis (CF) is mainly determined
by pulmonary disease and has dramatically improved over the
last few decades. In the United States, the mean life expectancy
increased from 6 months when the disease was first described,
to 35 years in 2005 [1,2]. Using a mathematical model to de-
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doi:10.1016/j.jcf.2008.07.005estimated for children born in 1990 and referred early to a
specialist centre [3]. Recently, a life expectancy of 50 years has
been claimed for children born around the year 2000 and this
appears realistic [4]. CF is a multi-systemic and complex di-
sease. It is commonly assumed that specialist management is the
best way of guaranteeing enough experience on this multi-
faceted condition and making available a dedicated team as well
as the numerous specialist interventions that might be necessary.
It also facilitates large enough clinical trials, which remains a
critical issue [5]. Early referral to a specialist healthcare centre is
considered as an important prognostic factor as highlighted in
consensus reports on optimal management of CF [6–8]. It is
also supported by those who convincingly advocate for efficient
neonatal screening, universally coupled with immediate referrald by Elsevier B.V. All rights reserved.
Table 1
Main characteristics of the whole study population (n=217), classified
according to the delay between age at diagnosis and age at referral
N2 years:
Group A
b2 years p Value
Delay between age at diagnosis and age at referral
N (%) 67 (30.9%) 150 (69.1%)
M (%) 47 48 NS (0.96)
Median age at diagnosis (years) 0.2 0.2 NS (0.11)
Median delay between
diagnosis and referral (years)
6.3 0.1 b0.001
Duration of follow-up in a
specialized centre
6.2±3.7 10.2±3.4 b0.0001
PS (%) 1.5 4.7 NS (0.44)
ΔF508/ΔF508 (%) 60.7 61.2 NS (0.94)
Age (years) 14±3.1 11.6±3.1 b0.0001
FVC (% pred) 91±21 96±19 NS (0.08)
FEV1 (% pred) 77.6±22.2 88.5±20.2 b0.001
BMI (Z score) −0.94±1.12 −0.62±1.08 b0.05
IBW (%) 96±12 97±11 NS (p=0.59)
PA prevalence (%) 41.8 16.7 0.0001
Data are presented as mean±SD unless otherwise stated. M: male, PS: pan-
creatic sufficient, ΔF508/ΔF508: patients homozygous for the ΔF508 CFTR
mutation, FVC: forced vital capacity, % pred: % predicted, FEV1: forced expi-
ratory volume in one second, BMI: body mass index, IBW: ideal body weight,
PA: Pseudomonas aeruginosa.
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concerning the impact of this centralization on lung disease
remain limited and except for one [9] are either biased due to
comparison with historical controls, and/or probably under-
powered [10–15]. Mahadeva et al. [9] compared two groups of
adults who had either received continuous care from paediatric
and adult CF centres (n=50) or had received neither paediatric
nor adult centre care for their CF (n=36). Excluding body mass
index as a covariate, FEV1 was significantly better in the first
group. However, these patients where significantly more often
colonized with Pseudomonas aeruginosa (PA) and this coloni-
zation occurred 5 years earlier. Studying this topic further might
be especially relevant as PA colonization adversely affects
the prognosis of CF and also because even though a growing
number of western regions or countries are about to implement
newborn screening for CF, some primary care physicians still
wish to retain the clinical management responsibilities at least
until the patients become obviously ill.
This study was conducted to test the hypothesis that children
suffering from CF who are early referred to a specialist centre
have a more favourable respiratory outcome than those referred
later on. As there is no definition of what a late referral is, a cut-
off level of 2 years was chosen based on the estimation that the
diagnosis of CF by screening anticipates diagnosis by more than
a year in 50% of cases [16] and after a preliminary analysis in a
single centre.
2. Methods
2.1. Overall model of CF care in Belgium
Since 1999, seven CF centres have been officially accredited
and financially supported by the national health system. All are
based in academic hospitals. Centres had to fulfill a number of
qualitative criteria (facilities and resources) closely derived from
the Cystic Fibrosis Trust's 1996 guidelines [17]. A minimum of
50 patients on full care was required. Shared care is not con-
sidered as an option in this small country. Despite a few local
initiatives, there is no national neonatal screening program.
This retrospective study initially involved these 7 centres.
Eligible patients fulfilled the following criteria: 1) age at the
last consultation in 2003 ranging from 6 to 18 years; 2) age at
diagnosis less than 8 years; 3) at least one available spirometry
data set and bacterial culture in 2003. Investigated data formed
part of those collected for the Belgian CF registry, for which a
written informed consent was obtained and included. FEV1,
weight (expressed as a percentage of ideal weight for height),
P. aeruginosa (PA) prevalence at the end of the year 2003
were the main outcome measures. Anthropometric parameters
and FEV1 were normalized utilizing Freeman's [18] and Knud-
son's [19] equations respectively. Patients who did not expec-
torate spontaneously underwent a full session of physiotherapy,
after which either expectorations were obtained or a deep
pharyngeal aspiration was performed.
Patients were classified into two groups according to the delay
between age at diagnosis and age at referral to an accredited
centre, an early referral being defined as a delay less than 2 years.To get more comparable groups (see infra), each late referred
patient (Group A, n=61) was then matched to a single early
referred patient on the basis of 2 criteria: same centre and as
closest age as possible. This defined Group B.
For the 2 groups of matched patients, additional data were
collected, including: % of neonatally screened patients, number
of respiratory cultures per patient in 2003, % of oropharyngeal
samples (as opposed to sputum) for bacteriological purpose at the
last visit of 2003, % of mucoid strains of PA and rate of chronic
colonization by PA according to Lee et al. [20] at the end of 2003,
number of hospitalisations and respiratory-related hospitalisations
between 1999 and 2003 (including home intravenous antibiotic
treatments), anthropometric data at the first visit at the centre.
Normally distributed data (when tested using the Kolmo-
gorov–Smirnov test) were expressed as mean±SD. Analysis
of differences between groups or within groups at referral
and at the end of 2003 was performed using unpaired or paired
t-tests. Not normally distributed data are expressed as me-
dians and differences between groups were evaluated with the
Mann–Whitney test. A chi-squared test was used for categorical
variables. Analysis of variance was performed to assess the im-
pact of PA prevalence (alone or in combination with the de-
lay between diagnosis and referral) on FEV1 in the two groups.
A p value b0.05 was considered significant.
3. Results
The 7 Belgian centres accepted to take part to the study. The
smallest centre proved to be unable to gather the data within
12 months. Table 1 summarizes main clinical characteristics of
217 patients from the 6 other centres according to the delay
between age at diagnosis and age at referral to a CF accredited
centre.
Table 2
Main characteristics of children after matching, based on same age, late referred
patients (GroupA) to a single early referred patient attending the same accredited
centre (Group B)
N2 years:
Group A
b2 years:
Group B
p Value
Delay between age at diagnosis and age at referral
N 57 57
Median delay between diagnosis
and referral (years)
6.1 0.1 b0.0001
Neonatally screened patients (%) 15.8 10.5 NS (0.57)
M (%) 47 42 NS (0.70)
Median age (years) at
diagnosis (IQR)
0.2 (0–0.6) 0.3 (0.1–1.82) NS (0.13)
Mean duration of follow-up in a
specialized centre
6.4±3.7 11.4±3.3 b0.0001
PS (%) 1.8 5.3 NS (0.61)
ΔF508/ΔF508 (%) 60 63.2 NS (0.87)
Age (years) 13.6±3.1 12.9±2.9 NS (0.24)
FVC (% pred) 91±21.6 94±16.1 NS (0.41)
FEV1 (% pred) 77.2±22.4 86.7±19.4 0.01
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centre less than 2 years following diagnosis and this pro-
portion was strikingly different among 6–9 y and 15–18 y old
children (88.3% vs 45.6% respectively, pb0.0001), reflecting
changes in the model of CF care in Belgium in the past two
decades.
Early referred patients had a significantly better FEV1 (88.5%
pred±20.2 vs 77.6% pred±22.2, pb0.001), lower prevalence
of PA (p=0.0001) and higher BMI (pb0.05). However it was
necessary to refine this comparison for three reasons: 1) early
referred patients were significantly younger (11.6 years±3.1
vs 14 years±3.1, pb0.0001); 2) the proportion of early
referred patients was very variable between centres, ranging
from 26% in centre numbered 5 to 86% in centre numbered 3;
3) there were striking differences in outcomes from different
centres (Fig. 1). In order to take into account these confounding
variables, each later referred patient was matched based on
same age to a single early referred patient attending the sameFig. 1. Major outcome parameters of the paediatric populations (6–17 years)
from the 6 main Belgian centres at the end of the year 2003 (mean — 95%
confidence interval for the mean).
Weight (% IBW) 92±14 95±19 NS (0.33)
BMI (Z score) −0.82±1.04 −0.62±1 NS (0.30)
Weight (Z score) −0.82±1.14 −0.66±1.15 NS (0.45)
Height (Z score) −0.25±1.40 −0.27±1.15 NS (0.91)
Median number of respiratory
cultures in 2003
5 5 NS (0.87)
Bacteriology: % of OP aspirates 30 42.1 NS (0.25)
PA prevalence (%) 38.6 17.5 0.021
Prevalence of mucoid PA (%) 24.6 12.3 NS (0.15)
Chronic colonization by PA (%) 33.3 21 NS (0.2)
Median number of hospitalisations
for respiratory problems in the
past 5 years
1 1 NS (0.53)
Data are presented as mean±SD unless otherwise stated. M: male, PS: pan-
creatic sufficient, ΔF508/ΔF508: patients homozygous for the ΔF508 CFTR
mutation, FVC: forced vital capacity, % pred: % predicted, FEV1: forced ex-
piratory volume in one second, IBW: ideal body weight, Pc: percentile, BMI:
body mass index, OP: oropharyngeal, PA: Pseudomonas aeruginosa.CF accredited centre. In the 2 centres with higher proportions of
late referred patients, a few of these could not be matched and
were discarded. Two more homogeneous groups of later re-
ferred (Group A) or early referred patients (Group B) could
then be compared. Table 2 summarizes these refined data.
Belgian CF children aged from 6 to 17 years, referred earlier to
a centre (less than 2 years after the diagnosis), have a more
favourable respiratory outcome than those referred later on.
Specifically, they had a 12% higher FEV1 at a mean age of
13 years (p=0.01) and PA prevalence in this group was about
two fold lower (pb0.05). Analysis of variance revealed a
strong association between PA and FEV1 (pb0.0001) but not
between FEV1 and the delay of referral. After adjustment for
the presence of PA, FEV1 was comparable in early and late
referred patients (p=0.45).
At the end of 2003, ideal body weight (Group A: 92%±14,
Group B: 95±11) and Z scores for BMI (GroupA: −0.82±1.04,
Group B: −0.62±1), weight (Group A: −0.82±1.14, Group B:
−0.66 ↑1 1.15) or height (Group A: −0.25±1.40, Group B:
−0.27±1.15) did not differ significantly between the 2 groups.
Anthropometric data at the first visit at the centre were
available for 49 children from Group A and 43 from Group B.
Table 3
Anthropometric data at the first visit at the centre and at the end of 2003
N2 years:
Group A
b2 years:
Group B
p Value
Delay between age at diagnosis and age at referral
n 49/57 43/57
Visit 1 Median
age (y)
6.6 0.8
BMI −0.80±1.15 −1.31±1.5 NS (0.07)
Weight −1.04±1.38 −1.20±1.57 NS (0.61)
Height −0.89±1.57 −0.95±0.58 NS (0.85)
End of 2003 Median
age (y)
14.4 13.3
BMI −0.75±1.03 −0.67±0.94 NS (0.66)
Weight −0.76±1.15 −0.64±1.02 NS (0.61)
Height −0.23±1.44 −0.22±1.06 NS (0.98)
Mean duration of
follow-up (y)
6.1±3.7 11.2±3.1
Δ BMI (Z score) at the
end of 2003
0.05±0.72 0.65±1.73 0.03
Data are presented as mean±SD unless otherwise stated. BMI (body mass
index), weight and height are expressed as Z score.
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these subgroups at the end of 2003. From the first visit tot the
end of 2003, a significant improvement was observed in early
referred patients in terms of BMI (pb0.05), weight (pb0.05)
and height (pb0.01), all expressed in Z score. In late referred
patients, weight and height improved significantly (pb0.05
andb0.001 respectively) but BMI did not (p=0.62).
4. Discussion
While avoiding the bias of most previous studies, this re-
trospective multicentric work demonstrates a more favourable
respiratory outcome in CF children if they are referred early to a
specialist centre. It is the first time that this benefit is reported
both in terms of FEV1 and PA prevalence. The functional
respiratory benefit observed in children referred early following
the diagnosis is important (12% FEV1 difference at a mean age
of 13 years). As FEV1 and PA infection are major prognostic
markers in CF, these data add important objective evidence to
support centralized treatment of patients with this disease.
While it is currently considered as unacceptable for an
isolated clinician to only refer a patient for severe complications
or when the disease has progressed too far [6], a complete
centralization for the care of CF patients can also present some
obstacles, including distances between a centre and a patient's
home – which is virtual in such as small country as Belgium –
and the problem of financing patient healthcare in specialist
centres [21]. Moreover, the possibility of an increased risk of
cross-infection for patients followed up in the centres has to be
taken into account. It is especially dreaded for PA infection
because chronic colonization by this bacteria has been asso-
ciated with the loss of nearly a third of life expectancy [22], a
less favourable FEV1 and an accelerated decline of this pa-
rameter [23,24], an increased treatment load affecting quality of
life and much higher treatment costs [25]. A link between at-
tendance at a centre and colonization by PA has been docu-mented [26], including in the context of neonatal screening [27].
In the latter study, increased colonization by this organism could
have masked part of the benefit derived from early diagnosis
and early specialist intervention.
Mahadeva's [9] study currently provides the most often cited
published evidence for early centralized care inCFpatients. These
authors reported a better FEV1 and chest X-ray score in CF adults
who had received continuous care from paediatric and adult CF
centres as compared to adults who never received centre care or
only received paediatric care at a CF centre.
Our work confirms the main conclusion of this study: earlier
specialist CF care is associated with a better FEV1. It strengthens
it in that the mean delay before referral in the late referred group
is much shorter (6.1 y) than in the Mahadeva's study.
In contrast to the findings of Mahedeva et al. however, we
observed that PA prevalence, mucoid PA prevalence and chronic
colonization rate by PA according to Lee all were lower in the
group of early referred patients though the difference was only
significant for PA prevalence. This was not obtained at the price of
a greater number of hospitalisations for respiratory problems in
the last 5 years of follow-up (see Table 3). Moreover, statistical
analysis showed that the benefit observed in terms of FEV1 in this
group was explained by the lower PA prevalence. This suggests
that a major contribution of early specialist CF care in Belgium
consisted of this achievement of lower PA prevalence. It is
actually now realized that a link between attendance at a centre
and earlier acquisition of PA is not a fatality, neither during regular
specialist CF care nor in the context of neonatal screening [28,29].
In reality it is largely manageable with a policy of patient
segregation based on bacteriology (applied to ambulatory as well
as hospitalised care), regular systematic bacteriological surveil-
lance and early intervention once this organism is detected [30].
Such policies have been put into practice in the 6 Belgian centres
studied, for more than 17 years in one centre and more than
7 years in 4 others, contributing to a low number of clusters in this
country [31] and a remarkably low prevalence of chronic
colonization by Pseudomonas in one centre [32].
Most anthropometric parameters of children significantly im-
proved from the first visit at the centre to the end of 2003. The
latter are in accordance with those reported in the literature [1] but
in contrast to Mahadeva's results the differences between early
and late referred patients were not significant. This finding was
unexpected since the benefit of early intervention in CF, in par-
ticular as a result of neonatal screening, was first and mainly
demonstrated through nutritional aspects [33]. Looking further at
the data at the first visit shows that the BMI (Z score) of early
referred patients tended to beworse (p=0.07). Taken together, the
data suggest that the nutritional aspect of the treatment was pretty
well managed by the general paediatricians before referral.
Another point highlighted by this work is the heterogeneity of
the outcomes variables obtained from the different centres. Such
differences have been recognized for a long time [34]. Their
amplitude can be astonishing in such a small country but is
comparable to that shown at the level of large epidemiologi-
cal studies and national registries during the past few years. These
differences are now drawing considerable attention as they
may provide an opportunity to develop quality improvement
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identification of a link between better lung function in 6- to
12 year-old children and clinical care patterns in infants in previous
years [36]. Yet, a comprehensive attempt to identify specific care
patterns associated with better outcome was beyond the scope of
this study.
Assuming an acceptable mean annual decline in FEV1 of
1–3%, a 20% difference in this major outcome variable be-
tween children with a mean age around 13 years from differ-
ent centres is impressive. It has such survival implications
that it might even pose ethical concerns at the level of the
National CF patients Association, rising the question of the
access of patients and/or their parents to this information.
From a different point of view, these results, which plead for
an early referral to specialist centres, are in agreement with the
accumulated body of evidence for neonatal screening, currently
in place or considered in a growing number of western countries.
In conclusion, this retrospective multicentric study clearly
shows that earlier referral of children suffering from CF to spe-
cialist care is associated with a significant pulmonary benefit, as
demonstrated by a markedly better FEV1 and lower PA preva-
lence at 13 years. The study also confirms, in a small country such
as Belgium, a wide disparity of results from different centres.
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